Abstract
Background: Patients with schizophrenia experience a higher risk of mortality and morbidity from physical health issues, including cardiovascular disease, diabetes, and metabolic syndrome. The literature suggests that patients with schizophrenia have a higher prevalence of metabolic syndrome than the general population. However, there is limited research examining the prevalence of hypertension (HTN), hyperlipidemia (HLD), and types 2 diabetes mellitus (T2DM) among patients with schizophrenia in large biobank data. Therefore, this study aims to investigate the prevalence of three disorders among patients with schizophrenia enrolled in All of Us database. Methods: In this cross-sectional study, we included participants from All of Us dataset version 6. Schizophrenia cohort was defined as having at least one ICD diagnosis code for schizophrenia and one or more antipsychotic exposure for schizophrenia. Patients with HTN, HLD, T2DM were identified using diagnosis codes, blood pressure measurements, medication history, and laboratory results (HbA1C, fasting, and random blood glucose). The prevalence of each disease was identified in schizophrenia cohort as well as all participants enrolled in the database, and odds ratios were calculated. Results: Of 258,188 individuals with available electronic health records data, 3,246 had schizophrenia. The median age was 51.8 (SD 13.1). 1,687 (52.0%) were males, 1,407 (43.3%) were African American, and 1015 (31.3%) were White. The prevalence of HTN, HLD, T2DM in participants with schizophrenia was 38.9%, 34.6%, 16.5%, respectively, compared to 21.6%, 22%, and 7.9% in all participants. The unadjusted odds ratios of HTN, HLD, T2DM in participants with schizophrenia compared to all participants were 2.344 (95% CI 2.182-2.561), 1.889 (95% CI 1.756-2.032), 2.336 (95% CI 2.125-2.563), respectively. Conclusion: Our analysis shows that the prevalence of HTN, HLD, T2DM is higher in individuals with schizophrenia compared to all participants in All of Us database. This highlights the importance of regular screening and prevention of cardiovascular disease risk factors in patients with schizophrenia. Future studies regarding the impact of these disorders on schizophrenia patients need to be undertaken.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
